Life Singularity Secures RMB 50 Million Series A Funding to Advance Precision Medicine Big Data Platform Vitark16™

On June 14, 2017, Life Singularity, a medical big data company, announced that it had secured RMB 50 million in financing led by Huiding Capital. The funds will be used for the research, development, and upgrading of its proprietary medical big data platform, Vitark16™, as well as for building nationwide research alliances focused on multiple disease types.

According to VCBeat, the company has now received total funding of nearly RMB 100 million.

Life Singularity is a high-tech enterprise dedicated to technological innovation in big data for precision medicine. The company has assembled an experienced, cross-disciplinary team comprising elites and international experts from the fields of clinical medicine, bioinformatics, and computational technology. The team includes several world-class biostatisticians and bioinformaticians, PhDs from prestigious universities worldwide, as well as senior engineers from renowned companies such as Baidu, IBM, and Microsoft.

International experts in medical big data are involved in the company’s top-level design, operational processes, and quality control systems. More than 80% of the company’s employees hold master’s degrees from prestigious universities. Their technical expertise spans multiple fields, including clinical information processing, biobanking, molecular diagnostics, bioinformatics, biostatistics, natural language processing, artificial intelligence, and distributed computing, collectively providing users with comprehensive solutions for precision medicine big data.

The company is committed to its mission of “leveraging biomedical big data and artificial intelligence technologies to ensure that everyone receives the most appropriate healthcare services.” Its independently developed core product, Vitark16™, has been deployed in more than 100 medical centers.

Vitark16™ is a big data platform that aggregates clinical information, omics data, and biological samples from multiple heterogeneous data sources. The platform integrates diagnostics, surgical procedures, pathology, imaging, laboratory tests, and follow-up data into a unified and standardized model, and features a built-in bio-omics data processing engine that includes genomic sequencing analysis and interpretation.

Vitark16™ is an intelligent big data platform. Leveraging deep learning algorithms built on robust cloud computing technology, the platform performs secondary analysis and mining of massive datasets, creating a “treasure trove” of precision medicine big data that features depth, breadth, and temporal span to support clinical evidence-based analysis. This enables clinical discovery and translational research, ultimately establishing a new generation of learning-based intelligent healthcare systems.

Under the traditional model of medical research, physicians and medical students must devote substantial time and energy to querying, organizing, and entering clinical data. In-depth analysis and item-by-item interpretation of genomic sequencing and proteomics data constitute an even more formidable undertaking. More importantly, despite significant investments of time, the output of research achievements remains highly uncertain.

Vitark16™ provides physicians with a one-stop solution ranging from data acquisition to in-depth data analysis.Leveraging the heuristic and visual data analytics platform of Vitark16™, Life Singularity enables physicians to efficiently structure multi-source, heterogeneous, and unstructured clinical information. The platform not only significantly reduces the workload associated with basic data processing but also facilitates the efficient extraction and generation of clinically translatable outcomes, fostering a virtuous cycle between research and clinical practice, thereby enhancing the productivity of medical big data and the efficiency of healthcare services.

The company has established partnerships with over 100 medical centers across China, including numerous large tertiary Grade A general hospitals and specialized hospitals.The Company will collaborate with these hospitals on the development and construction of a precision medicine big data platform, and assist in establishing multiple nationwide research consortia. Some projects have already achieved phased results.

Building on this foundation, the company will continue to expand its coverage to contribute to advancing clinical research at partner hospitals, developing genomic sequencing data, and promoting the application of clinical assistants for precision medicine.

Despite the “capital winter” experienced by Chinese internet companies in recent years, capital enthusiasm has only intensified in the fields of clinical genetic testing and precision medicine. Precision medicine, underpinned by comprehensive medical big data and artificial intelligence platforms, is poised to unlock a vast market.

Following this round of financing, Life Singularity is accelerating the translation of medical center achievements into practical applications. Meanwhile, we sincerely invite elite talents from various professional fields—including clinical medicine, molecular diagnostics, biostatistics, machine learning, natural language processing, and distributed platform development—to join us. By fostering the collision of ideas, we aim to advance human medical health.